 | • レポートコード：MRC2-11QY01129 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は肝炎治療薬のグローバル市場について調査・分析したレポートです。種類別（VEMLIDY、EPCLUSA、SOVALDI、INCIVEK、OLYSIO、VICTRELIS、VIREAD、HEPSERA、BARACLUDE、TYZEKA）市場規模、用途別（A型肝炎、B型肝炎、C型肝炎、D型肝炎、E型肝炎）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別肝炎治療薬の競争状況、市場シェア ・世界の肝炎治療薬市場：種類別市場規模 2015年-2020年（VEMLIDY、EPCLUSA、SOVALDI、INCIVEK、OLYSIO、VICTRELIS、VIREAD、HEPSERA、BARACLUDE、TYZEKA） ・世界の肝炎治療薬市場：種類別市場規模予測 2021年-2026年（VEMLIDY、EPCLUSA、SOVALDI、INCIVEK、OLYSIO、VICTRELIS、VIREAD、HEPSERA、BARACLUDE、TYZEKA） ・世界の肝炎治療薬市場：用途別市場規模 2015年-2020年（A型肝炎、B型肝炎、C型肝炎、D型肝炎、E型肝炎） ・世界の肝炎治療薬市場：用途別市場規模予測 2021年-2026年（A型肝炎、B型肝炎、C型肝炎、D型肝炎、E型肝炎） ・北米の肝炎治療薬市場分析：米国、カナダ ・ヨーロッパの肝炎治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの肝炎治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の肝炎治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの肝炎治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：F. Hoffmann-La Roche、Gilead Sciences、GlaxoSmithKline、Johnson & Johnson、Merck、Novartis、Vertex Pharmaceuticals、Abbvie、Achillion Pharmaceuticals、Bristol-Myers Squibb ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.
Factors such as growth in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
Market Analysis and Insights: Global Hepatitis Drugs Market
The global Hepatitis Drugs market size is projected to reach US$ 70820 million by 2026, from US$ 56350 million in 2020, at a CAGR of 23.8%% during 2021-2026.
Global Hepatitis Drugs Scope and Market Size
Hepatitis Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hepatitis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hepatitis Drugs market is segmented into
VEMLIDY
EPCLUSA
SOVALDI
INCIVEK
OLYSIO
VICTRELIS
VIREAD
HEPSERA
BARACLUDE
TYZEKA
Segment by Application, the Hepatitis Drugs market is segmented into
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
Regional and Country-level Analysis
The Hepatitis Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hepatitis Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hepatitis Drugs Market Share Analysis
Hepatitis Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hepatitis Drugs business, the date to enter into the Hepatitis Drugs market, Hepatitis Drugs product introduction, recent developments, etc.
The major vendors covered:
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis
Vertex Pharmaceuticals
Abbvie
Achillion Pharmaceuticals
Bristol-Myers Squibb
1 Study Coverage
1.1 Hepatitis Drugs Product Introduction
1.2 Market Segments
1.3 Key Hepatitis Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hepatitis Drugs Market Size Growth Rate by Type
1.4.2 VEMLIDY
1.4.3 EPCLUSA
1.4.4 SOVALDI
1.4.5 INCIVEK
1.4.6 OLYSIO
1.4.7 VICTRELIS
1.4.8 VIREAD
1.4.9 HEPSERA
1.4.10 BARACLUDE
1.4.11 TYZEKA
1.5 Market by Application
1.5.1 Global Hepatitis Drugs Market Size Growth Rate by Application
1.5.2 Hepatitis A
1.5.3 Hepatitis B
1.5.4 Hepatitis C
1.5.5 Hepatitis D
1.5.6 Hepatitis E
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hepatitis Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hepatitis Drugs Revenue 2015-2026
2.1.2 Global Hepatitis Drugs Sales 2015-2026
2.2 Global Hepatitis Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hepatitis Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hepatitis Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hepatitis Drugs Competitor Landscape by Players
3.1 Hepatitis Drugs Sales by Manufacturers
3.1.1 Hepatitis Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hepatitis Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hepatitis Drugs Revenue by Manufacturers
3.2.1 Hepatitis Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hepatitis Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hepatitis Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hepatitis Drugs Revenue in 2019
3.2.5 Global Hepatitis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hepatitis Drugs Price by Manufacturers
3.4 Hepatitis Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hepatitis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hepatitis Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hepatitis Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hepatitis Drugs Market Size by Type (2015-2020)
4.1.1 Global Hepatitis Drugs Sales by Type (2015-2020)
4.1.2 Global Hepatitis Drugs Revenue by Type (2015-2020)
4.1.3 Hepatitis Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hepatitis Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hepatitis Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hepatitis Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hepatitis Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hepatitis Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hepatitis Drugs Market Size by Application (2015-2020)
5.1.1 Global Hepatitis Drugs Sales by Application (2015-2020)
5.1.2 Global Hepatitis Drugs Revenue by Application (2015-2020)
5.1.3 Hepatitis Drugs Price by Application (2015-2020)
5.2 Hepatitis Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hepatitis Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hepatitis Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hepatitis Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hepatitis Drugs by Country
6.1.1 North America Hepatitis Drugs Sales by Country
6.1.2 North America Hepatitis Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hepatitis Drugs Market Facts & Figures by Type
6.3 North America Hepatitis Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hepatitis Drugs by Country
7.1.1 Europe Hepatitis Drugs Sales by Country
7.1.2 Europe Hepatitis Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hepatitis Drugs Market Facts & Figures by Type
7.3 Europe Hepatitis Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hepatitis Drugs by Region
8.1.1 Asia Pacific Hepatitis Drugs Sales by Region
8.1.2 Asia Pacific Hepatitis Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hepatitis Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hepatitis Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hepatitis Drugs by Country
9.1.1 Latin America Hepatitis Drugs Sales by Country
9.1.2 Latin America Hepatitis Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hepatitis Drugs Market Facts & Figures by Type
9.3 Central & South America Hepatitis Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hepatitis Drugs by Country
10.1.1 Middle East and Africa Hepatitis Drugs Sales by Country
10.1.2 Middle East and Africa Hepatitis Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hepatitis Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hepatitis Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Corporation Information
11.1.2 F. Hoffmann-La Roche Description and Business Overview
11.1.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 F. Hoffmann-La Roche Hepatitis Drugs Products Offered
11.1.5 F. Hoffmann-La Roche Related Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Corporation Information
11.2.2 Gilead Sciences Description and Business Overview
11.2.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Gilead Sciences Hepatitis Drugs Products Offered
11.2.5 Gilead Sciences Related Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Description and Business Overview
11.3.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Hepatitis Drugs Products Offered
11.3.5 GlaxoSmithKline Related Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Corporation Information
11.4.2 Johnson & Johnson Description and Business Overview
11.4.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Johnson & Johnson Hepatitis Drugs Products Offered
11.4.5 Johnson & Johnson Related Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description and Business Overview
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Hepatitis Drugs Products Offered
11.5.5 Merck Related Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Description and Business Overview
11.6.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Novartis Hepatitis Drugs Products Offered
11.6.5 Novartis Related Developments
11.7 Vertex Pharmaceuticals
11.7.1 Vertex Pharmaceuticals Corporation Information
11.7.2 Vertex Pharmaceuticals Description and Business Overview
11.7.3 Vertex Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Vertex Pharmaceuticals Hepatitis Drugs Products Offered
11.7.5 Vertex Pharmaceuticals Related Developments
11.8 Abbvie
11.8.1 Abbvie Corporation Information
11.8.2 Abbvie Description and Business Overview
11.8.3 Abbvie Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Abbvie Hepatitis Drugs Products Offered
11.8.5 Abbvie Related Developments
11.9 Achillion Pharmaceuticals
11.9.1 Achillion Pharmaceuticals Corporation Information
11.9.2 Achillion Pharmaceuticals Description and Business Overview
11.9.3 Achillion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Achillion Pharmaceuticals Hepatitis Drugs Products Offered
11.9.5 Achillion Pharmaceuticals Related Developments
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Corporation Information
11.10.2 Bristol-Myers Squibb Description and Business Overview
11.10.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Bristol-Myers Squibb Hepatitis Drugs Products Offered
11.10.5 Bristol-Myers Squibb Related Developments
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Corporation Information
11.1.2 F. Hoffmann-La Roche Description and Business Overview
11.1.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 F. Hoffmann-La Roche Hepatitis Drugs Products Offered
11.1.5 F. Hoffmann-La Roche Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hepatitis Drugs Market Estimates and Projections by Region
12.1.1 Global Hepatitis Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hepatitis Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hepatitis Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hepatitis Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hepatitis Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hepatitis Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hepatitis Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hepatitis Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hepatitis Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hepatitis Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hepatitis Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hepatitis Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hepatitis Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hepatitis Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hepatitis Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hepatitis Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hepatitis Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hepatitis Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hepatitis Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hepatitis Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hepatitis Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hepatitis Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hepatitis Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hepatitis Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hepatitis Drugs Market Segments
Table 2. Ranking of Global Top Hepatitis Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hepatitis Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of VEMLIDY
Table 5. Major Manufacturers of EPCLUSA
Table 6. Major Manufacturers of SOVALDI
Table 7. Major Manufacturers of INCIVEK
Table 8. Major Manufacturers of OLYSIO
Table 9. Major Manufacturers of VICTRELIS
Table 10. Major Manufacturers of VIREAD
Table 11. Major Manufacturers of HEPSERA
Table 12. Major Manufacturers of BARACLUDE
Table 13. Major Manufacturers of TYZEKA
Table 14. Global Hepatitis Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 15. Global Hepatitis Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 16. Global Hepatitis Drugs Sales by Regions 2015-2020 (K MT)
Table 17. Global Hepatitis Drugs Sales Market Share by Regions (2015-2020)
Table 18. Global Hepatitis Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Hepatitis Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 20. Global Hepatitis Drugs Sales Share by Manufacturers (2015-2020)
Table 21. Global Hepatitis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Hepatitis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatitis Drugs as of 2019)
Table 23. Hepatitis Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Hepatitis Drugs Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Hepatitis Drugs Price (2015-2020) (USD/MT)
Table 26. Hepatitis Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Hepatitis Drugs Product Type
Table 28. Date of International Manufacturers Enter into Hepatitis Drugs Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Hepatitis Drugs Sales by Type (2015-2020) (K MT)
Table 31. Global Hepatitis Drugs Sales Share by Type (2015-2020)
Table 32. Global Hepatitis Drugs Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Hepatitis Drugs Revenue Share by Type (2015-2020)
Table 34. Hepatitis Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 35. Global Hepatitis Drugs Sales by Application (2015-2020) (K MT)
Table 36. Global Hepatitis Drugs Sales Share by Application (2015-2020)
Table 37. North America Hepatitis Drugs Sales by Country (2015-2020) (K MT)
Table 38. North America Hepatitis Drugs Sales Market Share by Country (2015-2020)
Table 39. North America Hepatitis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Hepatitis Drugs Revenue Market Share by Country (2015-2020)
Table 41. North America Hepatitis Drugs Sales by Type (2015-2020) (K MT)
Table 42. North America Hepatitis Drugs Sales Market Share by Type (2015-2020)
Table 43. North America Hepatitis Drugs Sales by Application (2015-2020) (K MT)
Table 44. North America Hepatitis Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Hepatitis Drugs Sales by Country (2015-2020) (K MT)
Table 46. Europe Hepatitis Drugs Sales Market Share by Country (2015-2020)
Table 47. Europe Hepatitis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Hepatitis Drugs Revenue Market Share by Country (2015-2020)
Table 49. Europe Hepatitis Drugs Sales by Type (2015-2020) (K MT)
Table 50. Europe Hepatitis Drugs Sales Market Share by Type (2015-2020)
Table 51. Europe Hepatitis Drugs Sales by Application (2015-2020) (K MT)
Table 52. Europe Hepatitis Drugs Sales Market Share by Application (2015-2020)
Table 53. Asia Pacific Hepatitis Drugs Sales by Region (2015-2020) (K MT)
Table 54. Asia Pacific Hepatitis Drugs Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Hepatitis Drugs Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Hepatitis Drugs Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Hepatitis Drugs Sales by Type (2015-2020) (K MT)
Table 58. Asia Pacific Hepatitis Drugs Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Hepatitis Drugs Sales by Application (2015-2020) (K MT)
Table 60. Asia Pacific Hepatitis Drugs Sales Market Share by Application (2015-2020)
Table 61. Latin America Hepatitis Drugs Sales by Country (2015-2020) (K MT)
Table 62. Latin America Hepatitis Drugs Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Hepatitis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Hepatitis Drugs Revenue Market Share by Country (2015-2020)
Table 65. Latin America Hepatitis Drugs Sales by Type (2015-2020) (K MT)
Table 66. Latin America Hepatitis Drugs Sales Market Share by Type (2015-2020)
Table 67. Latin America Hepatitis Drugs Sales by Application (2015-2020) (K MT)
Table 68. Latin America Hepatitis Drugs Sales Market Share by Application (2015-2020)
Table 69. Middle East and Africa Hepatitis Drugs Sales by Country (2015-2020) (K MT)
Table 70. Middle East and Africa Hepatitis Drugs Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Hepatitis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Hepatitis Drugs Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Hepatitis Drugs Sales by Type (2015-2020) (K MT)
Table 74. Middle East and Africa Hepatitis Drugs Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Hepatitis Drugs Sales by Application (2015-2020) (K MT)
Table 76. Middle East and Africa Hepatitis Drugs Sales Market Share by Application (2015-2020)
Table 77. F. Hoffmann-La Roche Corporation Information
Table 78. F. Hoffmann-La Roche Description and Major Businesses
Table 79. F. Hoffmann-La Roche Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 80. F. Hoffmann-La Roche Product
Table 81. F. Hoffmann-La Roche Recent Development
Table 82. Gilead Sciences Corporation Information
Table 83. Gilead Sciences Description and Major Businesses
Table 84. Gilead Sciences Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 85. Gilead Sciences Product
Table 86. Gilead Sciences Recent Development
Table 87. GlaxoSmithKline Corporation Information
Table 88. GlaxoSmithKline Description and Major Businesses
Table 89. GlaxoSmithKline Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 90. GlaxoSmithKline Product
Table 91. GlaxoSmithKline Recent Development
Table 92. Johnson & Johnson Corporation Information
Table 93. Johnson & Johnson Description and Major Businesses
Table 94. Johnson & Johnson Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 95. Johnson & Johnson Product
Table 96. Johnson & Johnson Recent Development
Table 97. Merck Corporation Information
Table 98. Merck Description and Major Businesses
Table 99. Merck Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 100. Merck Product
Table 101. Merck Recent Development
Table 102. Novartis Corporation Information
Table 103. Novartis Description and Major Businesses
Table 104. Novartis Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 105. Novartis Product
Table 106. Novartis Recent Development
Table 107. Vertex Pharmaceuticals Corporation Information
Table 108. Vertex Pharmaceuticals Description and Major Businesses
Table 109. Vertex Pharmaceuticals Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 110. Vertex Pharmaceuticals Product
Table 111. Vertex Pharmaceuticals Recent Development
Table 112. Abbvie Corporation Information
Table 113. Abbvie Description and Major Businesses
Table 114. Abbvie Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 115. Abbvie Product
Table 116. Abbvie Recent Development
Table 117. Achillion Pharmaceuticals Corporation Information
Table 118. Achillion Pharmaceuticals Description and Major Businesses
Table 119. Achillion Pharmaceuticals Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 120. Achillion Pharmaceuticals Product
Table 121. Achillion Pharmaceuticals Recent Development
Table 122. Bristol-Myers Squibb Corporation Information
Table 123. Bristol-Myers Squibb Description and Major Businesses
Table 124. Bristol-Myers Squibb Hepatitis Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 125. Bristol-Myers Squibb Product
Table 126. Bristol-Myers Squibb Recent Development
Table 127. Global Hepatitis Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 128. Global Hepatitis Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 129. Global Hepatitis Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 130. Global Hepatitis Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 131. North America: Hepatitis Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 132. North America: Hepatitis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Europe: Hepatitis Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 134. Europe: Hepatitis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Asia Pacific: Hepatitis Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 136. Asia Pacific: Hepatitis Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 137. Latin America: Hepatitis Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 138. Latin America: Hepatitis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Middle East and Africa: Hepatitis Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 140. Middle East and Africa: Hepatitis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 142. Key Challenges
Table 143. Market Risks
Table 144. Main Points Interviewed from Key Hepatitis Drugs Players
Table 145. Hepatitis Drugs Customers List
Table 146. Hepatitis Drugs Distributors List
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatitis Drugs Product Picture
Figure 2. Global Hepatitis Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. VEMLIDY Product Picture
Figure 4. EPCLUSA Product Picture
Figure 5. SOVALDI Product Picture
Figure 6. INCIVEK Product Picture
Figure 7. OLYSIO Product Picture
Figure 8. VICTRELIS Product Picture
Figure 9. VIREAD Product Picture
Figure 10. HEPSERA Product Picture
Figure 11. BARACLUDE Product Picture
Figure 12. TYZEKA Product Picture
Figure 13. Global Hepatitis Drugs Sales Market Share by Application in 2020 & 2026
Figure 14. Hepatitis A
Figure 15. Hepatitis B
Figure 16. Hepatitis C
Figure 17. Hepatitis D
Figure 18. Hepatitis E
Figure 19. Hepatitis Drugs Report Years Considered
Figure 20. Global Hepatitis Drugs Market Size 2015-2026 (US$ Million)
Figure 21. Global Hepatitis Drugs Sales 2015-2026 (K MT)
Figure 22. Global Hepatitis Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 23. Global Hepatitis Drugs Sales Market Share by Region (2015-2020)
Figure 24. Global Hepatitis Drugs Sales Market Share by Region in 2019
Figure 25. Global Hepatitis Drugs Revenue Market Share by Region (2015-2020)
Figure 26. Global Hepatitis Drugs Revenue Market Share by Region in 2019
Figure 27. Global Hepatitis Drugs Sales Share by Manufacturer in 2019
Figure 28. The Top 10 and 5 Players Market Share by Hepatitis Drugs Revenue in 2019
Figure 29. Hepatitis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 30. Global Hepatitis Drugs Sales Market Share by Type (2015-2020)
Figure 31. Global Hepatitis Drugs Sales Market Share by Type in 2019
Figure 32. Global Hepatitis Drugs Revenue Market Share by Type (2015-2020)
Figure 33. Global Hepatitis Drugs Revenue Market Share by Type in 2019
Figure 34. Global Hepatitis Drugs Market Share by Price Range (2015-2020)
Figure 35. Global Hepatitis Drugs Sales Market Share by Application (2015-2020)
Figure 36. Global Hepatitis Drugs Sales Market Share by Application in 2019
Figure 37. Global Hepatitis Drugs Revenue Market Share by Application (2015-2020)
Figure 38. Global Hepatitis Drugs Revenue Market Share by Application in 2019
Figure 39. North America Hepatitis Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 40. North America Hepatitis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 41. North America Hepatitis Drugs Sales Market Share by Country in 2019
Figure 42. North America Hepatitis Drugs Revenue Market Share by Country in 2019
Figure 43. U.S. Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 44. U.S. Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. Canada Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. Canada Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. North America Hepatitis Drugs Market Share by Type in 2019
Figure 48. North America Hepatitis Drugs Market Share by Application in 2019
Figure 49. Europe Hepatitis Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 50. Europe Hepatitis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 51. Europe Hepatitis Drugs Sales Market Share by Country in 2019
Figure 52. Europe Hepatitis Drugs Revenue Market Share by Country in 2019
Figure 53. Germany Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 54. Germany Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. France Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 56. France Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. U.K. Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 58. U.K. Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Italy Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 60. Italy Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Russia Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. Russia Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Europe Hepatitis Drugs Market Share by Type in 2019
Figure 64. Europe Hepatitis Drugs Market Share by Application in 2019
Figure 65. Asia Pacific Hepatitis Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 66. Asia Pacific Hepatitis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 67. Asia Pacific Hepatitis Drugs Sales Market Share by Region in 2019
Figure 68. Asia Pacific Hepatitis Drugs Revenue Market Share by Region in 2019
Figure 69. China Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. China Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Japan Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Japan Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. South Korea Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. South Korea Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. India Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. India Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Australia Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Australia Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Taiwan Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Taiwan Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Indonesia Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 82. Indonesia Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Thailand Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 84. Thailand Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Malaysia Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 86. Malaysia Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Philippines Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 88. Philippines Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Vietnam Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Vietnam Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Asia Pacific Hepatitis Drugs Market Share by Type in 2019
Figure 92. Asia Pacific Hepatitis Drugs Market Share by Application in 2019
Figure 93. Latin America Hepatitis Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 94. Latin America Hepatitis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 95. Latin America Hepatitis Drugs Sales Market Share by Country in 2019
Figure 96. Latin America Hepatitis Drugs Revenue Market Share by Country in 2019
Figure 97. Mexico Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 98. Mexico Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Brazil Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 100. Brazil Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Argentina Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Argentina Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Latin America Hepatitis Drugs Market Share by Type in 2019
Figure 104. Latin America Hepatitis Drugs Market Share by Application in 2019
Figure 105. Middle East and Africa Hepatitis Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 106. Middle East and Africa Hepatitis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 107. Middle East and Africa Hepatitis Drugs Sales Market Share by Country in 2019
Figure 108. Middle East and Africa Hepatitis Drugs Revenue Market Share by Country in 2019
Figure 109. Turkey Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 110. Turkey Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. Saudi Arabia Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 112. Saudi Arabia Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 113. U.A.E Hepatitis Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 114. U.A.E Hepatitis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 115. Middle East and Africa Hepatitis Drugs Market Share by Type in 2019
Figure 116. Middle East and Africa Hepatitis Drugs Market Share by Application in 2019
Figure 117. North America Hepatitis Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. North America Hepatitis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Europe Hepatitis Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 120. Europe Hepatitis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Asia Pacific Hepatitis Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 122. Asia Pacific Hepatitis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Latin America Hepatitis Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 124. Latin America Hepatitis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Middle East and Africa Hepatitis Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 126. Middle East and Africa Hepatitis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Porter's Five Forces Analysis
Figure 128. Channels of Distribution
Figure 129. Distributors Profiles
Figure 130. Bottom-up and Top-down Approaches for This Report
Figure 131. Data Triangulation
Figure 132. Key Executives Interviewed
C型肝炎治療薬の世界市場（～2026年） Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc. Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepa…- B型肝炎治療薬の世界市場（～2026年） Market Analysis and Insights: Global Hepatitis B Therapeutics Market The global Hepatitis B Therapeutics market size is projected to reach US$ 2568.8 million by 2026, from US$ 2489 million in 2020, at a CAGR of 3.0%% during 2021-2026. Global Hepatitis B Therapeutics Scope and Market Size Hepatitis B…
- B型肝炎ウイルス（HBV）の世界市場（～2026年） Over the recent years, the global Hepatitis B Treatment industry has been driven by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infectio…
- 肝炎検査診断の世界市場（～2026年） Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic condition. Hepatitis testing refer…
- 予防的B型肝炎ウイルスワクチンの世界市場（～2026年） The main objective of hepatitis B immunization strategies is to prevent chronic hepatitis B virus infection and its serious consequences, including liver cirrhosis and hepatocellular cancer. The increasing prevalence and incidence of hepatitis B infection is the dominant factor of driving the growth…